[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nishtar Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":162},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,75,106,134],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100643160","dentin-hypersensitivity-in-orthodontic-patients-triple-blinded-randomized-trial-of-three-desensitizing-agents-100643160",false,"NCT07641322","Dentin Hypersensitivity in Orthodontic Patients: Triple-Blinded, Randomized Trial of Three Desensitizing Agents.","Dentin Hypersensitivity: Triple-Blinded, Multicenter Randomized Trial of Three Desensitizing Dentifrices vs Non-Desensitizing Control","Inclusion Criteria:\n\n* Orthodontic patients aged 18-40 years.\n* Presence of mild to moderate dentin hypersensitivity (VAS ≥ 4).\n* Willingness to comply with a 12-week follow-up period.\n* No active periodontal disease or untreated caries.\n* Not pregnant or breastfeeding.\n* No history of allergy to desensitizing agents\n\nExclusion Criteria:\n\n* o Patients with systemic conditions affecting oral health (e.g., diabetes, immunocompromised).\n\n  * Patients using medications that affect tooth sensitivity (e.g., anti-inflammatory drugs).",true,"ALL","18 Years","40 Years",{"count":21,"type":22},200,"ESTIMATED","INTERVENTIONAL",[25],"NA","The effect of desensitizing agents will be studied on dentin hypersensitivity in orthodontic patients.it is a randomized controlled trial. three experimental groups and one placebo group.",[28],"Dentin Desensitizing Agents","NOT_YET_RECRUITING","2026-06-07",{"date":32,"type":33},"2026-06-11","ACTUAL",{"date":35,"type":22},"2026-07-15",{"date":37,"type":22},"2026-12-15",{"name":39,"class":40},"Nishtar Medical University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":48,"targetDuration":4,"studyType":23,"phases":50,"briefSummary":52,"conditions":53,"keywords":58,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},"100608995","phase-2-comparison-of-submucosal-dexamethasone-and-methylprednisolone-in-postoperative-sequelae-of-parasymphsis-fractures-100608995","NCT07208799","Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures","Comparison of Effectiveness of Submucosal Dexamethasone and Methylprednisolone in Management of Postoperative Sequelae in Mandibular Parasymphysis Fractures","Inclusion Criteria:\n\n1. Patients aged 18 to 40.\n2. Both Gender.\n3. Fracture less than a week old.\n4. Isolated mandibular parasymphysis fractures.\n\nExclusion Criteria:\n\n* 1\\. Immunocompromised patients (due to increased risk of infection and complications).\n\n  2\\. Patients experiencing acute pain from conditions such as pulpitis, abscesses, or other acute infections (to ensure that acute pain does not confound the study results).\n\n  3\\. Patients reporting hypersensitivity to steroids (to avoid adverse reactions).\n\n  4\\. Patients taking or requiring prophylactic antibiotics or anti-inflammatory drugs before surgery (to prevent confounding effects on study outcomes).\n\n  5\\. Patients with a history of systemic steroid administration for 15 days (as this could affect the study's outcomes).\n\n  6\\. Patients with chronic pain problems or mental disorders (to maintain consistency in response to treatment).\n\n  7\\. Patients with comminuted fractures (to maintain consistency in fracture type).\n\n  8\\. Pregnant or lactating women (to avoid potential risks to the fetus and nursing infant).\n\n  9\\. Smokers who smoke at least 10 cigarettes per day for 2 years (to minimize the impact of smoking on healing and recovery).\n\nria:",{"count":49,"type":22},72,[51],"PHASE2","The rationale of the current research is to address the limitation of existing knowledge as it is not clear which of the two drugs (Dexamethasone or Methylprednisolone) is more effective in reduction of postoperative sequelae in patient with mandibular parasymphysis fracture. This study fills the gap by providing sound evidence on the preferred steroid option to help clinicians have more data to make decisions and improve patients' health. The result of this research will then be added to the evidence-based protocols for the treatment of parasymphysis fractures.",[54,55,56,57],"Mandible Fracture","Edema Face","Pain Management","Corticosteroid Injection",[59,60,61,62,63,64],"mandible fracture","edema","pain","submucosal","dexamethasone","methylprednisolone","RECRUITING","2026-04-02",{"date":68,"type":33},"2026-04-06",{"date":70,"type":33},"2026-01-03",{"date":72,"type":22},"2026-12-01",{"name":39,"class":40},1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":83,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":74},"100615145","phase-4-vitamin-d-for-preventing-recurrent-preeclampsia-in-pregnant-women-100615145","NCT07288801","Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women","Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia\n\nExclusion Criteria:\n\n* Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record)\n* Women presenting with intra-uterine death of the fetus.","FEMALE","20 Years","45 Years",{"count":86,"type":22},146,[88],"PHASE4","The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is:\n\nDoes vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia?\n\nTo answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study.\n\nParticipants will be randomly assigned to two equal groups:\n\n* Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation.\n* Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D.\n\nWhile on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140\u002F90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded.\n\nAt the end, researchers will compare how many women in each group developed recurrent pre-eclampsia.\n\nThis study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.",[91,92,93],"Pre-eclampsia","Pregnancy","Vitamin D",[95,96,97,93],"pre-eclampsia","pregnancy","recurrence","2025-12-04",{"date":100,"type":33},"2025-12-17",{"date":102,"type":33},"2025-08-09",{"date":104,"type":22},"2026-02-08",{"name":39,"class":40},{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":82,"minAge":18,"maxAge":84,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":115,"briefSummary":116,"conditions":117,"keywords":120,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":74},"100605310","phase-4-letrozole-plus-misoprostol-versus-misoprostol-alone-for-treating-women-with-missed-miscarriage-100605310","NCT07160855","Letrozole Plus Misoprostol Versus Misoprostol Alone for Treating Women With Missed Miscarriage","Comparison of Letrozole With Misoprostol Versus Misoprostol Alone in the Management of Missed Miscarriages","Inclusion Criteria:\n\n* Pregnant women up till 13th weeks of gestation according to last menstrual period (LMP) dates, confirmed on ultrasound\n* Single intrauterine pregnancy\n* Planned for termination due to missed miscarriage\n\nExclusion Criteria:\n\n* Previous history of cesarean section\n* Uterine scar due to previous procedure like myomectomy",{"count":114,"type":22},92,[88],"The goal of this clinical trial is to learn whether adding the medicine letrozole to Misoprostol helps women have a complete abortion more often than using Misoprostol alone for the treatment of missed miscarriage (when a pregnancy has stopped developing but has not yet passed naturally).\n\nThe main questions this study aims to answer are:\n\n1. Does taking letrozole for 3 days before misoprostol increase the chance of a complete abortion compared to misoprostol alone?\n2. Does the use of letrozole affect the time it takes for abortion to occur? Who can Join? i. Women up to 13 weeks of pregnancy (based on last menstrual period and confirmed by ultrasound) who have a missed miscarriage.\n\nii. Only those with a single pregnancy are eligible. iii. Women with a previous cesarean section or uterine scar are not included.\n\nWhat Will Happen in the Study A total of 92 women will take part.\n\nParticipants will be randomly assigned to one of two groups:\n\nGroup A: Letrozole tablets once daily for 3 days, followed by one dose of vaginal misoprostol.\n\nGroup B: Placebo tablets for maximum of 3 days, followed by one dose of vaginal misoprostol.\n\nDoctors will monitor whether the abortion is complete within 24 hours. If it is not, other medical procedures will be offered as needed.\n\nProducts of conception will be examined to confirm abortion.",[118,119],"Miscarriage in First Trimester","Missed Miscarriage",[121,122,123,124,125],"Abortion, missed","Abortion, induced","Letrozole","Misoprostol","first trimester","2025-08-29",{"date":128,"type":33},"2025-09-08",{"date":130,"type":33},"2025-05-13",{"date":132,"type":22},"2025-11-12",{"name":39,"class":40},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":17,"minAge":141,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":149,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":159,"leadSponsor":161,"locationsCount":74},"100585100","phase-4-comparison-of-intralesional-triamcinolone-versus-verapamil-for-keloid-treatment-100585100","NCT06897969","Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment","Comparison of Intralesional Triamcinolone and Intralesional Verapamil in the Treatment of Keloids","Inclusion Criteria:\n\n* size of keloid1-5 cm,\n* on any site of the body,\n* duration less then five years and\n* baseline Vancouver scar score of more the or equal to 5\n\nExclusion Criteria:\n\n* Pregnant or lactating women,\n* family history of keloids,\n* acromegaly, and\n* congestive cardiac diseases","10 Years","50 Years",{"count":144,"type":22},60,[88],"This study aims to compare the efficacy of intralesional triamcinolone and verapamil in patients presenting with keloid at our local setting. The results will guide us towards better management of keloids by choosing the more appropriate treatment. Adequate treatment will reduce significant emotional and physical distress in patients. We hypothesized that mean reduction in Vancouver Scar Score is higher in triamcinolone acetonide group compared to verapamil after three months of treatment.",[148],"Keloid Scars",[150,151,152,153,154],"Keloid","Vancouver scar scale","Triamcinolone","Verapamil","Intralesional injection","2025-03-26",{"date":157,"type":33},"2025-04-01",{"date":157,"type":22},{"date":160,"type":22},"2025-09-30",{"name":39,"class":40},""]